ReviewCell insight2026
Construction and application of mammary and breast cancer organoids.
Review in Cell insight, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mammary organoids and breast cancer organoids (BCOs) have become indispensable models for investigating mammary development, tumorigenesis, therapeutic response, and drug resistance. In this review, we summarize current strategies for constructing mammary organoids from adult mammary stem cells, pluripotent stem cells and immortalized mammary epithelial cell lines, and discuss how these models recapitulate key physiological processes. Additionally, we elaborate on four complementary approaches for building BCOs, including patient-derived tumor organoids (PDOs), gene-edited models, microenvironment reconstruction via multicellular co-culture, and organoid-on-a-chip platforms. Notably, we outline major applications of mammary organoids in developmental biology and translational fields, and emphasize the expanding roles of BCOs in living biobanks, mechanistic studies, high-throughput drug screening, personalized drug sensitivity testing, and immunotherapy response prediction. Finally, we point out key challenges including standardization, long-term genetic and phenotypic stability, vascularization, immune-context integration, and optimization of dynamic culture conditions, and propose directions to improve model fidelity and clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.